Menu
sharewise is moving On the weekend of 22/23 August the new sharewise becomes the main site. Have a look now and tell us what you miss. Go to the new sharewise What changes
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

EQS-News: Newron präsentiert Daten und Updates zu seinem klinischen Programm zur Entwicklung von Evenamide als Zusatztherapie bei Schizophrenie auf dem Weltkongress für Biologische Psychiatrie (WCBP) 2025Photo, wide shot, wide-angle lens, soft focus,  Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Hiroshi Sugimoto: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-d5U47McddROtnUwv1JIaZvc2.png?st=2023-05-04T16%3A11%3A57Z&se=2023-05-04T18%3A11%3A57Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-04T16%3A04%3A37Z&ske=2023-05-05T16%3A04%3A37Z&sks=b&skv=2021-08-06&sig=KvGLXJQj4L2uYw31IYBsPpHX4telRq/7natMW2uEF58%3D
EQS-News: Newron präsentiert Daten und Updates zu seinem klinischen Programm zur Entwicklung von Evenamide als Zusatztherapie bei Schizophrenie auf dem Weltkongress für Biologische Psychiatrie (WCBP) 2025
EQS-News: Newron präsentiert Daten und Updates zu seinem klinischen Programm zur Entwicklung von Evenamide als Zusatztherapie bei Schizophrenie auf dem Weltkongress für Biologische Psychiatrie (WCBP) 2025
EQS-News: Heidelberg Pharma gibt die Präsentation neuer klinischer Daten des führenden ATAC-Kandidaten HDP-101 auf der International Myeloma Society-Jahrestagung 2025 bekanntPhoto, wide shot, wide-angle lens, soft focus,  Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Hiroshi Sugimoto: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-d5U47McddROtnUwv1JIaZvc2.png?st=2023-05-04T16%3A11%3A57Z&se=2023-05-04T18%3A11%3A57Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-04T16%3A04%3A37Z&ske=2023-05-05T16%3A04%3A37Z&sks=b&skv=2021-08-06&sig=KvGLXJQj4L2uYw31IYBsPpHX4telRq/7natMW2uEF58%3D
EQS-News: Heidelberg Pharma gibt die Präsentation neuer klinischer Daten des führenden ATAC-Kandidaten HDP-101 auf der International Myeloma Society-Jahrestagung 2025 bekannt
EQS-News: Heidelberg Pharma gibt die Präsentation neuer klinischer Daten des führenden ATAC-Kandidaten HDP-101 auf der International Myeloma Society-Jahrestagung 2025 bekannt
EQS-Adhoc: Heidelberg Pharmas Partner Telix Pharmaceuticals informiert über Stand des Zulassungsantrags für sein Diagnostikum TLX250-CDxPhoto, wide shot, wide-angle lens, soft focus,  Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Hiroshi Sugimoto: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-d5U47McddROtnUwv1JIaZvc2.png?st=2023-05-04T16%3A11%3A57Z&se=2023-05-04T18%3A11%3A57Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-04T16%3A04%3A37Z&ske=2023-05-05T16%3A04%3A37Z&sks=b&skv=2021-08-06&sig=KvGLXJQj4L2uYw31IYBsPpHX4telRq/7natMW2uEF58%3D
EQS-Adhoc: Heidelberg Pharmas Partner Telix Pharmaceuticals informiert über Stand des Zulassungsantrags für sein Diagnostikum TLX250-CDx
EQS-Adhoc: Heidelberg Pharmas Partner Telix Pharmaceuticals informiert über Stand des Zulassungsantrags für sein Diagnostikum TLX250-CDx
Summit Therapeutics Aktie: Durchbruch bei Lungenkrebs!Photo, wide shot, wide-angle lens, soft focus,  Biotech company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Hiroshi Sugimoto: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-pKgbwxVSbyTCu0UzPNe8NL8D.png?st=2023-05-04T16%3A02%3A58Z&se=2023-05-04T18%3A02%3A58Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-04T12%3A13%3A51Z&ske=2023-05-05T12%3A13%3A51Z&sks=b&skv=2021-08-06&sig=%2BhYssNp3W0HiZMxCV64XVELyP8stYUjFhgUVfPrTLyg%3D
Summit Therapeutics Aktie: Durchbruch bei Lungenkrebs!

Die Biotech-Aktie von Summit Therapeutics zeigt sich volatil, nachdem Partner Akeso vielversprechende Studienergebnisse für…

Der Beitrag Summit Therapeutics Aktie: Durchbruch bei Lungenkrebs!

Samsung SDI Aktie: Radikaler StrategiewechselPhoto, wide shot, wide-angle lens,  Mental health care service, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ce3b930-5e2a-4215-b686-0ad0eb0b922a.png
Samsung SDI Aktie: Radikaler Strategiewechsel

Samsung SDI vollzieht einen markanten Strategiewandel und teilt erstmals Kerntechnologien für die Batterieproduktion mit…

Der Beitrag Samsung SDI Aktie: Radikaler Strategiewechsel erschien zuerst

AT&T-Aktie: Überraschender Werbeschub durch LinkedInPhoto, wide shot, wide-angle lens,  Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Michael Light: https://img.theapi.app/temp/c28f6640-54ba-4d2b-afbe-b5fd3b0ee19e.png
AT&T-Aktie: Überraschender Werbeschub durch LinkedIn

AT&T Business überrascht mit einer strategischen Partnerschaft, die dem Technologie-Segment des Telekom-Riesen neuen Schwung…

Der Beitrag AT&T-Aktie: Überraschender Werbeschub durch LinkedIn

3 Biotech Catalysts Present Major OpportunityPhoto, wide shot, wide-angle lens,  Pharmaceutical company, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ae4a134-dd01-4c80-a621-18399f5a2541.png
3 Biotech Catalysts Present Major Opportunity

For biotech firms, a bit of positive news—a key result from clinical trials or new drug discovery, say—can be the difference between a major rally based on a path toward sustained profitability

Which States Have the Highest Interest Rates on Family Loans? [2025 Survey]Photo, wide shot, wide-angle lens,  Mental health care service, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ce3b930-5e2a-4215-b686-0ad0eb0b922a.png
Which States Have the Highest Interest Rates on Family Loans? [2025 Survey]

When people talk about “the Bank of Mom & Dad,” they usually picture interest-free loans and flexible repayment terms. 

But as our new state-by-state breakdown shows (based on a survey of over

NanoRepro Aktie: Kräftige Wachstumszahlen!Photo, wide shot, wide-angle lens, soft focus,  Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Hiroshi Sugimoto: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-d5U47McddROtnUwv1JIaZvc2.png?st=2023-05-04T16%3A11%3A57Z&se=2023-05-04T18%3A11%3A57Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-04T16%3A04%3A37Z&ske=2023-05-05T16%3A04%3A37Z&sks=b&skv=2021-08-06&sig=KvGLXJQj4L2uYw31IYBsPpHX4telRq/7natMW2uEF58%3D
NanoRepro Aktie: Kräftige Wachstumszahlen!

Ein Kursziel von 4,50 Euro für eine Aktie, die bei 1,92 Euro notiert –…

Der Beitrag NanoRepro Aktie: Kräftige Wachstumszahlen! erschien zuerst auf kapitalmarktexperten.de.

Quelle kapitalmarktexperte

Hyra Network gewinnt den renommierten Chairman’s Award 2025 beim WITSA Global AI SummitPhoto, wide shot, wide-angle lens,  Clinical research organization, sunset photo at golden hour, photo by Peter Lik: https://img.midjourneyapi.xyz/temp/02f7778c-d723-4fb3-bdef-fabb7e5fc9c8.png
Hyra Network gewinnt den renommierten Chairman’s Award 2025 beim WITSA Global AI Summit

TAIPEI, Taiwan, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Hyra Network, ein Vorreiter im Bereich dezentrale KI und souveräne digitale Infrastruktur, wurde auf dem WITSA Global AI Summit, der von der World

EQS-News: NanoRepro AG: Aktuelle GBC-Studie mit Kursziel 4,50 EuroPhoto, wide shot, wide-angle lens, soft focus,  Biotech company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Hiroshi Sugimoto: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-pKgbwxVSbyTCu0UzPNe8NL8D.png?st=2023-05-04T16%3A02%3A58Z&se=2023-05-04T18%3A02%3A58Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-04T12%3A13%3A51Z&ske=2023-05-05T12%3A13%3A51Z&sks=b&skv=2021-08-06&sig=%2BhYssNp3W0HiZMxCV64XVELyP8stYUjFhgUVfPrTLyg%3D
EQS-News: NanoRepro AG: Aktuelle GBC-Studie mit Kursziel 4,50 Euro
EQS-News: NanoRepro AG: Aktuelle GBC-Studie mit Kursziel 4,50 Euro
Meet the Vanguard ETF That's Crushing the S&P 500 and Nasdaq-100 Despite Not Owning Micron, Sandisk, or Any of the "Magnificent Seven" Stocks: https://g.foolcdn.com/editorial/images/883414/a-person-in-a-coffee-shop-looking-at-a-computer.jpg
Meet the Vanguard ETF That's Crushing the S&P 500 and Nasdaq-100 Despite Not Owning Micron, Sandisk, or Any of the "Magnificent Seven" Stocks

Sandisk (NASDAQ: SNDK) has been by far the best-performing S&P 500 (SNPINDEX: ^GSPC) stock in 2026 with a 544% year to date gain as of the market close on Aug. 13. Sandisk is followed by Dell

Advanced Micro Devices vs. monday.com: Comparing Revenue Trends Between These High-Growth Tech Companies: https://g.foolcdn.com/charts/production/processed/amd-mndy/quarter/revenue/bar/primary/standard/limit-12/latest/amd-mndy_quarter_revenue_bar_primary_standard_limit12.png
Advanced Micro Devices vs. monday.com: Comparing Revenue Trends Between These High-Growth Tech Companies

Advanced Micro Devices (NASDAQ:AMD) primarily generates revenue by designing, developing, and selling advanced microprocessors, discrete graphics processing units, and highly customized

Advanced Micro Devices vs. AppLovin: Which Technology Stock Is a Better Buy in 2026?: https://cdn.content.foolcdn.com/images/1umn9qeh/production/df62d03add0a26cc05ef3d45b8f39a15145fe783-1200x800.png?w=800&q=75&fit=max&auto=format
Advanced Micro Devices vs. AppLovin: Which Technology Stock Is a Better Buy in 2026?

Investors face a choice between hardware and software dominance as Advanced Micro Devices (NASDAQ:AMD) and AppLovin (NASDAQ:APP) compete for capital in an increasingly artificial intelligence-driven

AST SpaceMobile Trades Near $74. Here's The Subscriber Math That Justifies It.: https://g.foolcdn.com/editorial/images/882776/satellites-in-orbit.jpg
AST SpaceMobile Trades Near $74. Here's The Subscriber Math That Justifies It.

AST SpaceMobile (NASDAQ: ASTS), a developer of low Earth orbit (LEO) satellites, went public through a merger with a special purpose acquisition company on April 7, 2021. It started trading at

The $1.3 Trillion Inference War Is Heating Up. 3 Stocks to Watch.: https://g.foolcdn.com/editorial/images/882711/gettyimages-1492319884.jpg
The $1.3 Trillion Inference War Is Heating Up. 3 Stocks to Watch.

Inference has become the fastest-growing part of the artificial intelligence (AI) infrastructure market, and Bloomberg Intelligence projects it will double the size of the AI training market by

AT&T Yields 4.7% and Trades At 8 Times Earnings. Is the SpaceX Threat Really Worth That Discount?: https://g.foolcdn.com/editorial/images/882286/couple-looks-at-smartphone-in-awe.jpg
AT&T Yields 4.7% and Trades At 8 Times Earnings. Is the SpaceX Threat Really Worth That Discount?

AT&T (NYSE: T) appears to face a significant threat from Space Exploration Technologies (NASDAQ: SPCX). COO Gwynne Shotwell announced that SpaceX's connectivity segment, Starlink, will compete with

3 Dividend-Paying Industrial Stocks to Buy in August: https://g.foolcdn.com/editorial/images/881500/gettyimages-1324119709.jpg
3 Dividend-Paying Industrial Stocks to Buy in August

The summer investing months are typically known for their sleepiness, with action picking up again in the final months to close out the year. But August is also a great time to do some portfolio

Advanced Micro Devices vs. Sandisk: Comparing the Latest Quarterly Revenue Trends as AI Demand Spikes Sales: https://g.foolcdn.com/charts/production/processed/amd-sndk/quarter/revenue/bar/primary/standard/limit-12/latest/amd-sndk_quarter_revenue_bar_primary_standard_limit12.png
Advanced Micro Devices vs. Sandisk: Comparing the Latest Quarterly Revenue Trends as AI Demand Spikes Sales

The AI explosion is presenting exciting opportunities for companies that previously may have been considered tier two players in their sectors. Advanced Micro Devices (NASDAQ:AMD) is a huge business

Stock Market Midday, Aug. 5: Eli Lilly Pops and AMD Drops in Mixed Morning MarketsPhoto, wide shot, wide-angle lens, soft focus,  Biotech company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Hiroshi Sugimoto: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-pKgbwxVSbyTCu0UzPNe8NL8D.png?st=2023-05-04T16%3A02%3A58Z&se=2023-05-04T18%3A02%3A58Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-04T12%3A13%3A51Z&ske=2023-05-05T12%3A13%3A51Z&sks=b&skv=2021-08-06&sig=%2BhYssNp3W0HiZMxCV64XVELyP8stYUjFhgUVfPrTLyg%3D
Stock Market Midday, Aug. 5: Eli Lilly Pops and AMD Drops in Mixed Morning Markets

As of 11:50 AM ET, the Dow Jones Industrial Average (DJINDICES:^DJI) is up 0.80% to 54,521, and the S&P 500 (SNPINDEX:^GSPC) has climbed 0.03% to 7,738, putting both in record-high territory. The Na

AMD's Data Center Business Doubled to $6.7 Billion. The Stock Fell 9% Because of What That Growth Costs.: https://g.foolcdn.com/editorial/images/882160/amd-headquarters-santa-clara-with-amd-logo-on-building_amd_advance.jpg
AMD's Data Center Business Doubled to $6.7 Billion. The Stock Fell 9% Because of What That Growth Costs.

Shares of Advanced Micro Devices (NASDAQ: AMD) fell about 9% in Tuesday's after-hours session after the chipmaker reported its second-quarter results. That was just hours after the stock closed the

Advanced Micro Devices vs. Intel: Which Technology Stock Is a Better Buy in 2026?: https://cdn.content.foolcdn.com/images/1umn9qeh/production/232304ef0caa6d6d9809b270afde92b613c990f1-1200x800.png?w=800&q=75&fit=max&auto=format
Advanced Micro Devices vs. Intel: Which Technology Stock Is a Better Buy in 2026?

The semiconductor landscape is shifting rapidly as artificial intelligence demands redefine hardware requirements for global enterprises. Choosing between Advanced Micro Devices Inc (NASDAQ:AMD) and

3 of the Best Dividend Stocks to Buy in August 2026: https://g.foolcdn.com/editorial/images/881704/a-happy-person-holding-money-in-front-of-their-computer.jpg
3 of the Best Dividend Stocks to Buy in August 2026

Dividend stocks can be highly valuable investments to hold for the long term. In addition to dividend income, they have the potential to generate slow but modest gains over time. The problem these

IonQ vs. Advanced Micro Devices: Comparing Revenue Trends Between a Quantum Computing Innovator and an Artificial Intelligence Giant: https://g.foolcdn.com/charts/production/processed/ionq-amd/quarter/revenue/bar/primary/standard/limit-8/latest/ionq-amd_quarter_revenue_bar_primary_standard_limit8.png
IonQ vs. Advanced Micro Devices: Comparing Revenue Trends Between a Quantum Computing Innovator and an Artificial Intelligence Giant

IonQ (NYSE:IONQ) primarily generates revenue by developing general-purpose quantum computing systems and providing access through various cloud services.

The company finalized its acquisition of

Nvidia vs. Advanced Micro Devices: Evaluating Revenue Growth Trajectories for These Artificial Intelligence Giants: https://g.foolcdn.com/charts/production/processed/nvda-amd/quarter/revenue/bar/primary/standard/limit-8/latest/nvda-amd_quarter_revenue_bar_primary_standard_limit8.png
Nvidia vs. Advanced Micro Devices: Evaluating Revenue Growth Trajectories for These Artificial Intelligence Giants

Nvidia (NASDAQ:NVDA) primarily generates its revenue by designing and supplying advanced graphics, compute, and networking solutions used heavily across gaming and high-performance computing